Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

10 Day Concomitant Versus 14 Day Hybrid Regimen as First Line H. Pylori Eradication Treatment in a High Clarithromycin Resistance Area. A Multicenter Randomized Equivalence Trial

NCT03592069 is registered in ClinicalTrials.gov with Alexandra Hospital, Athens, Greece as lead sponsor.

NCT NCT03592069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03592069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
10 Day Concomitant Versus 14 Day Hybrid Regimen as First Line H. Pylori Eradication Treatment in a High Clarithromycin Resistance Area. A Multicenter Randomized Equivalence Trial
Lead sponsor
Alexandra Hospital, Athens, Greece
Phase
Phase 4
Overall status
Completed
Start date
February 21, 2018
Completion date
January 31, 2021
Enrollment
345 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

h. pylori associated phlegmonous gastritis, h.pylori gastrointestinal disease, h.pylori infection